Company intelligence / Profile preview

RBD

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

RBD Biotech is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the development of mRNA-based vaccines and therapeutics. The company utilizes its proprietary mRNA platform to address critical needs in infectious diseases and oncology. Its lead candidate, RBD-1016, is an mRNA vaccine targeting the SARS-CoV-2 virus that has progressed into late-stage clinical trials. In addition to its vaccine portfolio, RBD Biotech is exploring the application of siRNA technologies for various therapeutic indications. The company aims to establish a comprehensive platform for nucleic acid drug discovery and manufacturing.

Therapeutic areas: OncologyInfectious Diseases
Modalities: mRNA-based drugsVaccineSmall interfering RNA
Industry: Biotech

Beyond the preview

Go deeper on RBD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RBD.

Explore the full profile